Katherine Ruiz De Luzuriaga
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 34 | 2022 | 704 | 5.500 |
Why?
|
| HIV Infections | 38 | 2022 | 953 | 5.270 |
Why?
|
| Herpesvirus 4, Human | 20 | 2025 | 199 | 3.240 |
Why?
|
| Anti-Retroviral Agents | 14 | 2019 | 76 | 2.370 |
Why?
|
| Infectious Disease Transmission, Vertical | 14 | 2020 | 80 | 2.150 |
Why?
|
| Infectious Mononucleosis | 11 | 2025 | 34 | 2.100 |
Why?
|
| Anti-HIV Agents | 8 | 2020 | 139 | 1.600 |
Why?
|
| CD8-Positive T-Lymphocytes | 12 | 2020 | 668 | 1.580 |
Why?
|
| DNA, Viral | 12 | 2020 | 230 | 1.550 |
Why?
|
| Proviruses | 5 | 2021 | 27 | 1.440 |
Why?
|
| Epstein-Barr Virus Infections | 6 | 2019 | 105 | 1.280 |
Why?
|
| Genetic Variation | 7 | 2021 | 392 | 1.100 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2021 | 279 | 1.080 |
Why?
|
| Viral Load | 15 | 2022 | 230 | 1.080 |
Why?
|
| RNA, Viral | 9 | 2020 | 266 | 1.010 |
Why?
|
| Viral Matrix Proteins | 5 | 2017 | 50 | 1.000 |
Why?
|
| B-Lymphocytes | 8 | 2016 | 562 | 0.970 |
Why?
|
| Immunologic Memory | 9 | 2017 | 282 | 0.960 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2019 | 636 | 0.960 |
Why?
|
| HIV Antibodies | 7 | 2020 | 146 | 0.900 |
Why?
|
| Antiretroviral Therapy, Highly Active | 9 | 2020 | 94 | 0.870 |
Why?
|
| Virus Latency | 7 | 2019 | 31 | 0.850 |
Why?
|
| Infant | 21 | 2020 | 1692 | 0.800 |
Why?
|
| Brain | 4 | 2021 | 1601 | 0.760 |
Why?
|
| Antibodies, Viral | 4 | 2025 | 325 | 0.720 |
Why?
|
| HIV Seropositivity | 1 | 2022 | 81 | 0.700 |
Why?
|
| Phylogeny | 9 | 2022 | 388 | 0.690 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2017 | 70 | 0.670 |
Why?
|
| Vaccines | 1 | 2022 | 96 | 0.650 |
Why?
|
| Antigens, Viral | 3 | 2020 | 130 | 0.650 |
Why?
|
| Immunodominant Epitopes | 3 | 2020 | 59 | 0.650 |
Why?
|
| Secondary Prevention | 3 | 2016 | 165 | 0.650 |
Why?
|
| Spleen | 1 | 2021 | 474 | 0.630 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 4 | 2018 | 60 | 0.610 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2020 | 112 | 0.590 |
Why?
|
| Adolescent | 21 | 2022 | 6296 | 0.550 |
Why?
|
| Humans | 60 | 2025 | 65168 | 0.540 |
Why?
|
| Viral Tropism | 3 | 2018 | 55 | 0.520 |
Why?
|
| Recombination, Genetic | 2 | 2020 | 254 | 0.490 |
Why?
|
| Infant, Newborn | 12 | 2022 | 1418 | 0.480 |
Why?
|
| Sequence Analysis, DNA | 8 | 2021 | 412 | 0.480 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 2 | 2025 | 19 | 0.480 |
Why?
|
| Virus Replication | 7 | 2017 | 323 | 0.480 |
Why?
|
| Influenza A virus | 4 | 2017 | 119 | 0.470 |
Why?
|
| HIV Envelope Protein gp120 | 3 | 2018 | 130 | 0.470 |
Why?
|
| Virus Integration | 1 | 2016 | 33 | 0.470 |
Why?
|
| Macrophages | 5 | 2022 | 1037 | 0.460 |
Why?
|
| Immunotherapy | 2 | 2021 | 274 | 0.450 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2019 | 184 | 0.440 |
Why?
|
| Leukocytes, Mononuclear | 7 | 2020 | 246 | 0.430 |
Why?
|
| Oropharynx | 1 | 2014 | 12 | 0.410 |
Why?
|
| Child, Preschool | 12 | 2020 | 2059 | 0.410 |
Why?
|
| CD4 Antigens | 2 | 2018 | 149 | 0.400 |
Why?
|
| Immunoglobulin G | 4 | 2020 | 465 | 0.380 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2019 | 168 | 0.330 |
Why?
|
| Viremia | 3 | 2015 | 46 | 0.330 |
Why?
|
| AIDS Vaccines | 3 | 2012 | 72 | 0.330 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2020 | 27 | 0.320 |
Why?
|
| Pregnancy | 8 | 2017 | 2370 | 0.320 |
Why?
|
| Female | 27 | 2025 | 33982 | 0.310 |
Why?
|
| Major Histocompatibility Complex | 1 | 2020 | 85 | 0.310 |
Why?
|
| Complementarity Determining Regions | 1 | 2019 | 33 | 0.300 |
Why?
|
| Immediate-Early Proteins | 1 | 2019 | 46 | 0.300 |
Why?
|
| Genome, Viral | 2 | 2018 | 144 | 0.300 |
Why?
|
| Genes, env | 3 | 2021 | 15 | 0.300 |
Why?
|
| Software | 2 | 2021 | 399 | 0.300 |
Why?
|
| HIV | 1 | 2019 | 67 | 0.290 |
Why?
|
| Cross Reactions | 4 | 2025 | 139 | 0.280 |
Why?
|
| Trans-Activators | 1 | 2019 | 320 | 0.270 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2017 | 92 | 0.260 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 106 | 0.260 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2017 | 129 | 0.250 |
Why?
|
| Genes, Immunoglobulin | 2 | 2007 | 33 | 0.250 |
Why?
|
| Antibodies, Neutralizing | 2 | 2018 | 217 | 0.250 |
Why?
|
| Receptors, CCR5 | 3 | 2018 | 59 | 0.240 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 312 | 0.240 |
Why?
|
| Young Adult | 7 | 2025 | 4811 | 0.230 |
Why?
|
| Influenza, Human | 1 | 2017 | 203 | 0.220 |
Why?
|
| Male | 20 | 2025 | 31020 | 0.220 |
Why?
|
| Adult | 17 | 2025 | 17331 | 0.220 |
Why?
|
| Child | 7 | 2020 | 4606 | 0.220 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 1967 | 0.210 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 68 | 0.210 |
Why?
|
| HLA-A2 Antigen | 4 | 2019 | 61 | 0.210 |
Why?
|
| Mutation | 6 | 2017 | 2655 | 0.210 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 662 | 0.200 |
Why?
|
| Evolution, Molecular | 1 | 2015 | 347 | 0.190 |
Why?
|
| Meninges | 1 | 2022 | 10 | 0.190 |
Why?
|
| Disease Reservoirs | 1 | 2012 | 10 | 0.190 |
Why?
|
| Cluster Analysis | 2 | 2021 | 261 | 0.180 |
Why?
|
| Transcriptome | 1 | 2015 | 399 | 0.180 |
Why?
|
| Amino Acids | 1 | 2022 | 148 | 0.170 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2011 | 28 | 0.170 |
Why?
|
| Amino Acid Sequence | 4 | 2019 | 1579 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 539 | 0.160 |
Why?
|
| Hepatitis B Vaccines | 1 | 2010 | 16 | 0.160 |
Why?
|
| Acute Disease | 4 | 2016 | 662 | 0.160 |
Why?
|
| Hepatitis B | 1 | 2010 | 28 | 0.160 |
Why?
|
| Sustained Virologic Response | 2 | 2020 | 10 | 0.160 |
Why?
|
| Proteomics | 1 | 2022 | 291 | 0.160 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 152 | 0.150 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 1008 | 0.150 |
Why?
|
| AIDS Serodiagnosis | 1 | 2009 | 19 | 0.150 |
Why?
|
| Antigens, CD | 1 | 2010 | 342 | 0.150 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 463 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2020 | 448 | 0.140 |
Why?
|
| HIV Antigens | 1 | 2008 | 18 | 0.140 |
Why?
|
| HIV Core Protein p24 | 1 | 2008 | 17 | 0.140 |
Why?
|
| Time Factors | 5 | 2014 | 3873 | 0.140 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 37 | 0.130 |
Why?
|
| Computational Biology | 2 | 2021 | 367 | 0.130 |
Why?
|
| Models, Immunological | 1 | 2007 | 85 | 0.130 |
Why?
|
| Peptide Fragments | 3 | 2019 | 414 | 0.130 |
Why?
|
| Base Sequence | 4 | 2016 | 1326 | 0.120 |
Why?
|
| Lymphocyte Activation | 4 | 2017 | 750 | 0.120 |
Why?
|
| Orthomyxoviridae | 1 | 2005 | 27 | 0.120 |
Why?
|
| HLA-DRB1 Chains | 1 | 2025 | 16 | 0.110 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 20 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2007 | 481 | 0.110 |
Why?
|
| Viral Vaccines | 1 | 2015 | 56 | 0.110 |
Why?
|
| Milk, Human | 1 | 2006 | 99 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2005 | 204 | 0.110 |
Why?
|
| Genotype | 3 | 2018 | 673 | 0.110 |
Why?
|
| Gene Expression | 4 | 2018 | 851 | 0.100 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2002 | 28 | 0.100 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 26 | 0.100 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2003 | 44 | 0.100 |
Why?
|
| Pediatrics | 1 | 2006 | 265 | 0.100 |
Why?
|
| Mothers | 3 | 2015 | 281 | 0.100 |
Why?
|
| Burkitt Lymphoma | 1 | 2003 | 74 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2016 | 5783 | 0.090 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 51 | 0.090 |
Why?
|
| Bayes Theorem | 1 | 2022 | 124 | 0.090 |
Why?
|
| Neonatal Screening | 1 | 2022 | 104 | 0.090 |
Why?
|
| Interferon-gamma | 2 | 2017 | 574 | 0.080 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2020 | 4 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2018 | 660 | 0.080 |
Why?
|
| Neutralization Tests | 2 | 2018 | 125 | 0.080 |
Why?
|
| Poxviridae | 1 | 2009 | 5 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2019 | 2618 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1282 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2010 | 1032 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2012 | 164 | 0.070 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 4 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 511 | 0.070 |
Why?
|
| Puerto Rico | 1 | 2019 | 138 | 0.070 |
Why?
|
| Receptors, Virus | 1 | 2018 | 73 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2022 | 6859 | 0.070 |
Why?
|
| Immunity, Heterologous | 1 | 2017 | 11 | 0.070 |
Why?
|
| Open Reading Frames | 1 | 2018 | 84 | 0.070 |
Why?
|
| Seroconversion | 1 | 2017 | 6 | 0.070 |
Why?
|
| Blood-Brain Barrier | 1 | 2017 | 87 | 0.060 |
Why?
|
| Convalescence | 1 | 2016 | 17 | 0.060 |
Why?
|
| Virion | 1 | 2017 | 122 | 0.060 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 80 | 0.060 |
Why?
|
| Sequence Alignment | 1 | 2016 | 297 | 0.060 |
Why?
|
| Infant Mortality | 1 | 2016 | 20 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 72 | 0.060 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2015 | 16 | 0.060 |
Why?
|
| Remission Induction | 1 | 2016 | 149 | 0.060 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2015 | 26 | 0.060 |
Why?
|
| Phagocytosis | 1 | 2016 | 257 | 0.060 |
Why?
|
| Developing Countries | 1 | 2016 | 87 | 0.060 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 134 | 0.050 |
Why?
|
| Monocytes | 1 | 2016 | 356 | 0.050 |
Why?
|
| Epitopes | 2 | 2005 | 290 | 0.050 |
Why?
|
| Genomics | 1 | 2018 | 384 | 0.050 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 279 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2015 | 94 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2005 | 491 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2016 | 741 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1140 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2016 | 166 | 0.050 |
Why?
|
| Lopinavir | 1 | 2012 | 5 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1554 | 0.050 |
Why?
|
| Ritonavir | 1 | 2012 | 15 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 1560 | 0.050 |
Why?
|
| Antibodies | 1 | 2012 | 187 | 0.040 |
Why?
|
| Risk | 1 | 2012 | 374 | 0.040 |
Why?
|
| Cell Line | 2 | 2018 | 2018 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2011 | 80 | 0.040 |
Why?
|
| HIV Protease Inhibitors | 1 | 2012 | 109 | 0.040 |
Why?
|
| Clone Cells | 1 | 2010 | 111 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 239 | 0.040 |
Why?
|
| Pharyngitis | 1 | 2010 | 14 | 0.040 |
Why?
|
| Streptococcus pyogenes | 1 | 2010 | 29 | 0.040 |
Why?
|
| Hepatitis B Antibodies | 1 | 2010 | 9 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2010 | 18 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2012 | 615 | 0.040 |
Why?
|
| United States | 2 | 2019 | 8209 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2010 | 135 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2010 | 64 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2010 | 84 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2010 | 374 | 0.040 |
Why?
|
| Vaccination | 1 | 2011 | 377 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 180 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 43 | 0.030 |
Why?
|
| Virus Physiological Phenomena | 1 | 2007 | 8 | 0.030 |
Why?
|
| Palatine Tonsil | 1 | 2007 | 9 | 0.030 |
Why?
|
| Virus Activation | 1 | 2007 | 23 | 0.030 |
Why?
|
| Immunoglobulin D | 1 | 2007 | 9 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2007 | 25 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 2007 | 28 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2015 | 1549 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2010 | 321 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 116 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 984 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2007 | 138 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 237 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2007 | 133 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2018 | 181 | 0.030 |
Why?
|
| Middle Aged | 2 | 2017 | 18252 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2006 | 18 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2008 | 541 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2186 | 0.030 |
Why?
|
| Genes, nef | 1 | 2005 | 5 | 0.030 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2005 | 11 | 0.030 |
Why?
|
| Chemokine CCL4 | 1 | 2005 | 14 | 0.030 |
Why?
|
| Genes, gag | 1 | 2005 | 10 | 0.030 |
Why?
|
| Transfection | 1 | 2008 | 700 | 0.030 |
Why?
|
| Gene Products, nef | 1 | 2005 | 13 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2012 | 916 | 0.030 |
Why?
|
| Genes, MHC Class I | 1 | 2005 | 26 | 0.030 |
Why?
|
| K562 Cells | 1 | 2005 | 58 | 0.030 |
Why?
|
| Gene Products, gag | 1 | 2005 | 65 | 0.030 |
Why?
|
| DNA Primers | 1 | 2005 | 301 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2005 | 90 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 360 | 0.030 |
Why?
|
| RNA Stability | 1 | 2015 | 104 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 1695 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 709 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2004 | 194 | 0.030 |
Why?
|
| Genes, Viral | 1 | 2003 | 56 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 849 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2013 | 38 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 414 | 0.020 |
Why?
|
| Protein Binding | 1 | 2018 | 1636 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 655 | 0.020 |
Why?
|
| Drug Resistance, Viral | 1 | 2004 | 159 | 0.020 |
Why?
|
| Cell Division | 1 | 2003 | 449 | 0.020 |
Why?
|
| Prevalence | 1 | 2006 | 1445 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2009 | 3310 | 0.020 |
Why?
|
| Peptides | 1 | 2005 | 589 | 0.020 |
Why?
|
| Logistic Models | 1 | 2004 | 1269 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1584 | 0.020 |
Why?
|
| Phenotype | 1 | 2003 | 1230 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2478 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 135 | 0.020 |
Why?
|
| Models, Biological | 1 | 2003 | 1185 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2703 | 0.020 |
Why?
|
| Risk Factors | 1 | 2014 | 5425 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 21292 | 0.010 |
Why?
|